Skip to content
Screener

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.09B-13.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$7.3B+157%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$136.7M+153%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$95.69M+50.3%
AbbVie logo
AbbVieABBV
$3.56B+155%
LBR
LB Pharmaceuticals IncLBRX
-$23.32M-186%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K

Valuation

See full
Market cap$602.19M-13.2%
Enterprise value$552.07M

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Calculated from MapLight Therapeutics, Inc.’s reported figures.

The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:25 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-224129

FAQ

What is MapLight Therapeutics, Inc.'s free cash flow?
MapLight Therapeutics, Inc. (MPLT) reported free cash flow of -$51.2M in Q1 2026.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about MapLight Therapeutics, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude